Table 1.
Summary of nucleolin-Hdm2 interactions
| Hdm2 Construct |
Nucleolin | |||||
|---|---|---|---|---|---|---|
| FL | NT | RBD1–4 | RBD1–2 | RBD3–4 | GFP | |
| FL | +++ positive |
++ positive |
+++ positive |
+/− | +/− | − negative |
| p53-BD | ++ | + | ++ | − | − | − |
| NLS/NES | +++ | +/− | +++ positive |
− | − | − |
| CA | − | − | − | n.d. | n.d. | − |
| CT | − | − negative |
− | n.d. | n.d. | − |
| RING | ++ | +++ negative |
++ | − | − | − |
| GST | − negative |
− | − | − | − | − |
The strength of the apparent interactions, derived from GST-binding assays using cell lysates expressing GFP-nucleolin (Figure 3 and 4), is indicated as follows: − none; −/+ v. weak; + weak, ++ moderate, +++ strong. Interactions that were not determined are indicated as n.d. The results from in vitro binding assays with in vitro translated nucleolin domains with GST-tagged purified Hdm2 proteins (Fig. 6) are listed as “positive” or “negative” binding where indicated.